Reuters logo
Actelion shares plunge on report it eyes "complicated" J&J deal
2016年11月29日 / 早上8点06分 / 10 个月前

Actelion shares plunge on report it eyes "complicated" J&J deal

ZURICH, Nov 29 (Reuters) - Shares in Swiss biotech company Actelion plunged on Tuesday after a report the company was not actively considering selling itself, but instead weighing a “complicated deal” to link with U.S. healthcare giant Johnson & Johnson.

Actelion shares fell more than 8 percent in early trading, after having risen sharply over the last four days to value the company at about $20 billion amid takeover speculation.

Johnson & Johnson approached Actelion Chief Executive Jean-Paul Clozel expecting him to reject a takeover, so it instead has focused on another proposal to take a major stake in the Swiss company while leaving it independent, the Financial Times reported late on Monday.

Actelion declined to comment on the FT report. A Johnson & Johnson spokesman also declined comment. (Reporting by John Miller, editing by Michael Shields)

我们的标准汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below